Amundi Sells 289,018 Shares of Sanofi $SNY

Amundi trimmed its stake in Sanofi (NASDAQ:SNY - Free Report) by 45.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 341,045 shares of the company's stock after selling 289,018 shares during the period. Amundi's holdings in Sanofi were worth $18,628,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Accent Capital Management LLC purchased a new position in Sanofi during the 1st quarter valued at about $29,000. Eastern Bank lifted its position in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares during the period. Golden State Wealth Management LLC lifted its position in Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares during the period. Brentview Investment Management LLC purchased a new position in Sanofi during the 1st quarter valued at about $42,000. Finally, UMB Bank n.a. lifted its position in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after acquiring an additional 264 shares during the period. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Morgan Stanley raised shares of Sanofi from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Tuesday, September 2nd. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $62.67.

Sanofi Stock Down 1.3%

NASDAQ:SNY traded down $0.62 on Friday, reaching $47.03. 2,728,115 shares of the stock traded hands, compared to its average volume of 2,650,921. The company's fifty day simple moving average is $48.64 and its 200 day simple moving average is $51.16. Sanofi has a 12 month low of $44.73 and a 12 month high of $60.12. The company has a market capitalization of $115.48 billion, a price-to-earnings ratio of 11.31, a PEG ratio of 1.13 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the prior year, the firm earned $1.73 earnings per share. The business's revenue was down 7.0% compared to the same quarter last year. Equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.